2026 Obesity Treatment Breakthrough: Hanmi Pharmaceutical’s GLP-1 Drug Eppe and the Synergy of Digital Health Management Platforms
AI 요약 정보
- Hanmi's Eppe approved as South Korea's 45th homegrown drug
- Eppe Phase 3 patients averaged BMI 32 and 9.75% weight loss
- Hanmi targets world's first Eppe-linked digital drug by 2028